A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...
Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Meiragtx Holdings (MGTX – Research Report) on March 14 and set a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback